BR0113629A - Inibidores da adesão celular mediada por alfa4 - Google Patents

Inibidores da adesão celular mediada por alfa4

Info

Publication number
BR0113629A
BR0113629A BR0113629-1A BR0113629A BR0113629A BR 0113629 A BR0113629 A BR 0113629A BR 0113629 A BR0113629 A BR 0113629A BR 0113629 A BR0113629 A BR 0113629A
Authority
BR
Brazil
Prior art keywords
cell adhesion
mediated cell
alpha4
adhesion inhibitors
halogen atom
Prior art date
Application number
BR0113629-1A
Other languages
English (en)
Inventor
Takayuki Kawaguchi
Sumihiro Nomura
Mikiko Tsukimoto
Toshiyuki Kume
Ila Sircar
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of BR0113629A publication Critical patent/BR0113629A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

"INIBIDORES DA ADESãO CELULAR MEDIADA POR ALFA~ 4~". A presente invenção refere-se a um derivado da fenilalanina de Fórmula (I) em que X^ 1^ é um átomo de halogênio, X^ 2^ é um átomo de halogênio, Q é um CH~ 2~R- que é um grupo carboxila que pode estar esterificado; ou um sal farmaceuticamente aceitável do mesmo.
BR0113629-1A 2000-08-31 2001-08-27 Inibidores da adesão celular mediada por alfa4 BR0113629A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22912800P 2000-08-31 2000-08-31
PCT/US2001/026594 WO2002018320A2 (en) 2000-08-31 2001-08-27 INHIBITORS OF α4 MEDIATED CELL ADHESION

Publications (1)

Publication Number Publication Date
BR0113629A true BR0113629A (pt) 2003-07-22

Family

ID=22859926

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113629-1A BR0113629A (pt) 2000-08-31 2001-08-27 Inibidores da adesão celular mediada por alfa4

Country Status (28)

Country Link
US (6) US7026501B2 (pt)
EP (1) EP1315694B1 (pt)
JP (1) JP3899022B2 (pt)
KR (1) KR100528049B1 (pt)
CN (1) CN1229334C (pt)
AR (1) AR034556A1 (pt)
AT (1) ATE292615T1 (pt)
AU (2) AU2001286778B2 (pt)
BR (1) BR0113629A (pt)
CA (1) CA2418054C (pt)
CZ (1) CZ303460B6 (pt)
DE (1) DE60109943T2 (pt)
DK (1) DK1315694T3 (pt)
ES (1) ES2240509T3 (pt)
HK (1) HK1052684B (pt)
HU (1) HUP0302693A3 (pt)
IL (2) IL154305A0 (pt)
MX (1) MXPA03001837A (pt)
MY (1) MY129000A (pt)
NO (1) NO327861B1 (pt)
NZ (1) NZ524043A (pt)
PL (1) PL206656B1 (pt)
PT (1) PT1315694E (pt)
RU (1) RU2250895C2 (pt)
SI (1) SI1315694T1 (pt)
TW (1) TWI224587B (pt)
WO (1) WO2002018320A2 (pt)
ZA (1) ZA200301039B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1288205B1 (en) 2000-08-18 2011-02-02 Ajinomoto Co., Inc. Novel phenylalanine derivatives
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
KR100876622B1 (ko) 2001-04-27 2008-12-31 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로[1,5-ａ]피리딘 화합물 및 그 의약
MY140707A (en) * 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
AU2003265398A1 (en) 2002-08-09 2004-02-25 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
ATE426600T1 (de) * 2002-10-22 2009-04-15 Eisai R&D Man Co Ltd 7-phenylpyrazolopyridinverbindungen
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
CA2531796A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
WO2005014534A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
RU2390520C2 (ru) 2003-12-22 2010-05-27 Адзиномото Ко., Инк. Новые производные фенилаланина
MY140489A (en) 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
JP4966017B2 (ja) 2004-12-20 2012-07-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 １−シクロプロピルメチル−４−［２−（３，３，５，５−テトラメチルシクロヘキシル）フェニル］ピペラジンの塩および結晶
US7410971B2 (en) 2004-12-24 2008-08-12 Eisai R&D Management Co., Ltd. 1,2-di(cyclic)substituted benzene compounds
NZ563739A (en) 2005-06-09 2009-12-24 Ucb Pharma Sa 2,6 Quinolinyl derivatives, processes for preparing them and their use as medicament
JP2009516729A (ja) * 2005-11-23 2009-04-23 アストラゼネカ アクチボラグ Ｌ−フェニルアラニン誘導体
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
US7855291B2 (en) 2005-12-29 2010-12-21 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
US7897763B2 (en) 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
BRPI0620756B1 (pt) * 2005-12-29 2021-06-01 Tersera Therapeutics Llc Derivados de aminoácido multicíclicos, formulação farmacêutica compreendendo os mesmos e seus usos para inibir a atividade de triptofano hidroxilase 1 (tph1)
WO2007092471A2 (en) * 2006-02-03 2007-08-16 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
WO2007091046A1 (en) * 2006-02-09 2007-08-16 Astrazeneca Ab Chemical compounds
HUE047230T2 (hu) * 2006-02-28 2020-04-28 Biogen Ma Inc Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
JP2009531304A (ja) * 2006-02-28 2009-09-03 エラン ファーマシューティカルズ，インコーポレイテッド α−４阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法
EP1991267B1 (en) 2006-03-03 2017-12-20 Biogen MA Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
MX2010001938A (es) * 2007-08-24 2010-03-11 Lexicon Pharmaceuticals Inc Metodos para preparar compuestos basados en 4-fenil-6-(2,2,2-trifl uoro-1-feniletoxi)pirimidina.
ES2396126T3 (es) 2008-04-15 2013-02-19 Eisai R&D Management Co., Ltd. Compuesto de 3-fenilpirazol[5,1-b]tiazol
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
WO2011048091A1 (en) * 2009-10-21 2011-04-28 Glaxo Group Limited Process for preparing a phenylalanine derivative
EP4152004A1 (en) 2010-01-11 2023-03-22 Biogen MA Inc. Assay for jc virus antibodies
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
US20150010563A1 (en) * 2012-02-21 2015-01-08 Massachusetts Eye & Ear Infirmary Methods for Treating Corneal and Conjunctival Inflammation and Inflammatory Disorders
EP3004334A4 (en) 2013-05-28 2016-12-21 Biogen Ma Inc METHODS OF EVALUATION RISK OF DEVELOPMENT OF PML
WO2018085552A1 (en) * 2016-11-02 2018-05-11 Saint Louis University Integrin antagonists
CR20210213A (es) 2018-10-30 2021-06-24 Gilead Sciences Inc Derivados de quinolina como inhibidores de la integrina alfa4beta7
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK148576A (da) 1975-04-18 1976-10-19 Boehringer Mannheim Gmbh Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling
AU691201B2 (en) 1993-11-01 1998-05-14 Japat Ltd. Endothelin receptor antagonists
AU694495B2 (en) 1994-03-28 1998-07-23 Ciba-Geigy Japan Limited Antagonists of endothelin receptors
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
JPH11505522A (ja) 1995-04-21 1999-05-21 ノバルティス・アクチエンゲゼルシャフト エンドセリン阻害剤としてのｎ−アロイルアミノ酸アミド
WO1998053818A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
JP2002512625A (ja) 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
CA2291762A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
DE69820614T2 (de) 1997-05-30 2004-09-30 Celltech Therapeutics Ltd., Slough Entzündungshemmende tyrosin-derivate
AU8163398A (en) 1997-06-23 1999-01-04 Pharmacia & Upjohn Company Inhibitors of alpha4beta1mediated cell adhesion
JP2001512137A (ja) 1997-07-31 2001-08-21 エラン・ファーマシューティカルズ・インコーポレーテッド Ｖｌａ−４により媒介される白血球の付着を阻害するジペプチド化合物
BR9811569A (pt) 1997-07-31 2000-09-19 Elan Pharm Inc Compostos que inibem a adesão de leucócito mediada por vla-4
CN1265674A (zh) 1997-07-31 2000-09-06 伊兰药品公司 能抑制由vla－4介导的白细胞粘连的4－氨基苯基丙氨酸化合物
WO1999006432A1 (en) 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4
AR016133A1 (es) 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
KR20010022413A (ko) 1997-07-31 2001-03-15 진 엠. 듀발 Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제하는 벤질화합물
EP1001972A1 (en) 1997-07-31 2000-05-24 Elan Pharmaceuticals, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
HUP0003921A3 (en) 1997-07-31 2001-03-28 Wyeth Corp Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
TR200000481T2 (tr) 1997-08-22 2000-06-21 F.Hoffmann-La Roche Ag N-Alkonoilfenilalenin türevleri.
JP3555876B2 (ja) 1997-08-22 2004-08-18 エフ．ホフマン−ラ ロシュ アーゲー Ｎ−アロイルフェニルアラニン誘導体
US6191171B1 (en) * 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
AU1463499A (en) 1997-11-21 1999-06-15 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
EP1034164B1 (en) 1997-11-24 2004-05-19 Merck & Co., Inc. Substituted beta-alanine derivatives as cell adhesion inhibitors
AU750175B2 (en) 1997-11-24 2002-07-11 Merck & Co., Inc. Cyclic amino acid derivatives as cell adhesion inhibitors
US6197794B1 (en) 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
EP1056714B1 (en) * 1998-02-26 2004-08-11 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
WO1999064395A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
TW591026B (en) 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
ES2220140T3 (es) 1998-12-22 2004-12-01 Tanabe Seiyaku Co., Ltd. Inhibidores de la adhesion mediada de celulas por alfa 4 beta 1 (a4b1).
GB2354440A (en) 1999-07-20 2001-03-28 Merck & Co Inc Aryl amides as cell adhesion inhibitors
AU6903200A (en) * 1999-08-16 2001-03-13 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
AU6909300A (en) * 1999-08-20 2001-03-19 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
EP1214292B1 (en) * 1999-09-24 2007-06-13 Genentech, Inc. Tyrosine derivatives
AU2001284649A1 (en) 2000-08-31 2002-03-13 Eli Lilly And Company Acetylenic sulfonamide derivatives

Also Published As

Publication number Publication date
WO2002018320A2 (en) 2002-03-07
US7671090B2 (en) 2010-03-02
WO2002018320A3 (en) 2002-06-06
HK1052684B (zh) 2005-07-22
CA2418054C (en) 2008-08-05
NO20030885L (no) 2003-02-25
AU2001286778B2 (en) 2005-02-10
RU2250895C2 (ru) 2005-04-27
US20050282900A1 (en) 2005-12-22
US7872151B2 (en) 2011-01-18
ATE292615T1 (de) 2005-04-15
NO327861B1 (no) 2009-10-05
HUP0302693A3 (en) 2005-05-30
US8501809B2 (en) 2013-08-06
CA2418054A1 (en) 2002-03-07
HUP0302693A2 (hu) 2003-12-29
CN1229334C (zh) 2005-11-30
CZ303460B6 (cs) 2012-09-26
KR20030059099A (ko) 2003-07-07
PL365668A1 (en) 2005-01-10
EP1315694B1 (en) 2005-04-06
ES2240509T3 (es) 2005-10-16
CZ2003487A3 (cs) 2003-06-18
US20110077299A1 (en) 2011-03-31
CN1449377A (zh) 2003-10-15
US20030176498A1 (en) 2003-09-18
DE60109943T2 (de) 2006-02-09
DE60109943D1 (de) 2005-05-12
US20090111879A1 (en) 2009-04-30
US7456217B2 (en) 2008-11-25
PT1315694E (pt) 2005-07-29
US20100113820A1 (en) 2010-05-06
ZA200301039B (en) 2004-02-09
MY129000A (en) 2007-03-30
EP1315694A2 (en) 2003-06-04
KR100528049B1 (ko) 2005-11-15
JP2004507519A (ja) 2004-03-11
AR034556A1 (es) 2004-03-03
US20130289109A1 (en) 2013-10-31
TWI224587B (en) 2004-12-01
IL154305A0 (en) 2003-09-17
PL206656B1 (pl) 2010-09-30
HK1052684A1 (en) 2003-09-26
NO20030885D0 (no) 2003-02-25
IL154305A (en) 2010-11-30
US7026501B2 (en) 2006-04-11
DK1315694T3 (da) 2005-08-08
NZ524043A (en) 2004-08-27
SI1315694T1 (en) 2005-10-31
MXPA03001837A (es) 2003-10-15
AU8677801A (en) 2002-03-13
JP3899022B2 (ja) 2007-03-28

Similar Documents

Publication Publication Date Title
BR0113629A (pt) Inibidores da adesão celular mediada por alfa4
BRPI0111596B8 (pt) Composto piridona, processo de produção do composto, composição farmacêutica, e uso do dito composto
BR9903571A (pt) Método para inibição de glicogênio fosforilase humano
BR9712959B1 (pt) nitratos orgánicos anti-trombóticos de inibidores da ace.
BR0112370A (pt) Derivados de glutaramida substituìda com ciclopentila como inibidores de endopeptidase neutra
BR9806413A (pt) Composto e uso do mesmo
BR0011097A (pt) Derivados de 5-fenil-piridina
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
BRPI0506719A (pt) composto, composição farmacêutica, e, uso de um composto
BR9916781A (pt) 4-oxo-1,4-dihidro-3-quinolinacarboxamidas comoagentes antivirais
BR0313846A (pt) Derivados de dioxano-2-alquilcarbamatos, sua preparação e sua aplicação em terapêutica
BRPI0409255A (pt) derivados de ácido 2-(8,9-dioxo-2,6-diazabi-ciclo(5.2.0)non-1(7)-en-2-il)alquil fosfÈnico e seu uso como antagonistas de receptores de d-asparto de -n-metila (nmda)
TR200103099T2 (tr) Fosfodiesteraz IVinhibitörü 1-amino triazoloc 4,3-a!kinazolin-5-on ve/veya-5-tionlar
BR0210531A (pt) Derivados de ácido sulfÈnico
BR9810163A (pt) Compostos ou suas composições
BR9916318A (pt) Compostos bicìclicos
DE60025744D1 (de) Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
BR0308027A (pt) Processo para preparação de um derivado de fenilalanina e seus intermediários
BR9814983A (pt) Derivado de bifenil-amidina, pró-medicamento; inibidor de coagulação sanguìnea, e, agentes profilático e terapêutico para trombose ou êmbolo.
ATE245141T1 (de) Benzolsulfonamidderivate
BR0102377A (pt) Inibidores de não-nucleosìdeo transcriptase reversa
BR0004709A (pt) Derivados de quinolin-4-ila ii
BR0307521A (pt) Inibidores de adesão da célula mediada por alfa l beta2 integrina
BR0013515A (pt) Inibidores de sintase de ácido graxo
BR9910112A (pt) Métodos para a inibição de mrp1

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MITSUBISHI TANABE PHARMA CORPORATION (JP)

Free format text: ALTERADO DE: TANABE SEIYAKU CO., LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07C 233/0, A61P 11/06

Ipc: C07C 233/00 (2011.01), A61P 11/06 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]